Yuki Katsuya

10PUBLICATIONS
54CO-AUTHORS
Molecular targetsHaematological tumoursRespiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 18, 2026
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.

|Jan 04, 2026
Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.

Keisuke Ikegami, Reiko Ando Makihara, Yuki Katsuya

|Dec 29, 2025
Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies.

Haruhi Makino, Suguru Fukuhara, Keiji Okinaka

|Jun 26, 2025
Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends.

Tomomi Sanomachi, Yuki Katsuya, Tetsuya Nakatsura

|Jan 20, 2025
A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.

Yuki Katsuya, Masafumi Ikeda, Takafumi Koyama

|Aug 14, 2024
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.

Takafumi Koyama, Kan Yonemori, Toshio Shimizu

Pageof 2

Frequent Collaborators

6 joint publications

Takafumi Koyama

6 joint publications

Noboru Yamamoto

5 joint publications

Jun Sato

3 joint publications

Toshio Shimizu